{"id":1107,"date":"2012-09-12T12:10:12","date_gmt":"2012-09-12T12:10:12","guid":{"rendered":"https:\/\/touchendocrinology.com\/2012\/09\/12\/age-rage-and-diabetic-nephropathy\/"},"modified":"2012-09-12T12:10:12","modified_gmt":"2012-09-12T12:10:12","slug":"age-rage-and-diabetic-nephropathy","status":"publish","type":"post","link":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/age-rage-and-diabetic-nephropathy\/","title":{"rendered":"AGE, RAGE and Diabetic Nephropathy"},"content":{"rendered":"

Diabetic nephropathy (DN) has become the most frequent cause of terminal renal failure in western countries. Its natural course has been well described and includes the development of functional and structural degenerative changes in the kidney. More specifically, glomerular membrane thickening, mesangial matrix expansion, microvascular changes, arteriolar hyalinosis and tubular degeneration are characteristic aspects of overt DN. In view of the marked increase in the incidence of type 2 diabetes, over the next few years it will be vital to determine the mechanisms underlying this pathology.
\n
\nDiabetic nephropathy (DN) has become the most frequent cause of terminal renal failure in western countries. Its natural course has been well described and includes the development of functional and structural degenerative changes in the kidney. More specifically, glomerular membrane thickening, mesangial matrix expansion, microvascular changes, arteriolar hyalinosis and tubular degeneration are characteristic aspects of overt DN. In view of the marked increase in the incidence of type 2 diabetes, over the next few years it will be vital to determine the mechanisms underlying this pathology. Hyperglycaemia is known to be implicated in the development of the above-mentioned degenerative changes and as a hyperglycemic state is associated with the formation of advanced glycation end-products (AGEs) it is likely that the latter play a major role in the pathogenesis of the changes that occur during DN. At the present time, new therapeutic approaches to limit the progression of DN are being investigated. Thus a fuller understanding of the mechanisms underlying AGE formation and the inhibitors thereof is of major importance in this respect. <\/p>\n

Introduction to Advanced Glycation End-products<\/b>
AGEs are toxic compounds that are formed from a link between a reducing sugar and an amino group on the lysine and arginine residue of certain proteins. Their toxicity, which is triggered by a chronic hyperglycaemic state associated with diabetes, can act in three different ways: via deposition in the tissues, through in situ formation, or by receptor activation. <\/p>\n

Advanced Glycation End-product Formation<\/i>
Three pathways can lead to AGE formation: the Maillard reaction, the polyol pathway, and glycoxidation (see Figure 1<\/i>).1<\/sup> Glycation, which was first described in 1912 by LC Maillard constitutes the main pathway; the activation of this process depends on the glucose concentrations, time and temperature and several stages are required before AGEs can be formed.2<\/sup> The reaction between sugar and proteins leads to the formation of a Schiff base within a short time period (minutes or hours), which then undergoes rearrangements to yield Amadori products. The latter products are subject to further rearrangements, following which they become intermediary glycation products such as glycated haemoglobin, which is used in clinical practice. The final step of the reaction leading to the formation of AGEs requires longer periods of time (i.e. months).3<\/sup> <\/p>\n

To view the full article in PDF or eBook formats, please click on the icons above.<\/b> <\/p>\n","protected":false},"excerpt":{"rendered":"

Diabetic nephropathy (DN) has become the most frequent cause of terminal renal failure in western countries. Its natural course has been well described and includes the development of functional and structural degenerative changes in the kidney. More specifically, glomerular membrane thickening, mesangial matrix expansion, microvascular changes, arteriolar hyalinosis and tubular degeneration are characteristic aspects of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1107","post","type-post","status-publish","format-standard","hentry","category-uncategorized","vocabulary_1-diabetes"],"acf":{"wpcf-article_introduction":"","wpcf-article_abstract":"Diabetes is a disease that is present worldwide and which is associated with a large number of potential complications including chronic kidney disease (CKD). Several factors have been implicated in the development of the latter, including advanced glycation end-products (AGEs), which are formed from the interaction between sugar and proteins. AGE toxicity may be triggered via different mechanisms, especially by receptor binding. Immunohistochemical studies have demonstrated the presence of AGEs in all renal structures (vessels, glomeruli, tubules and the interstitium). They appear to be involved in the exacerbation of renal injury observed during diabetic nephropathy. At present, no specific treatment is yet available, although several therapeutic approaches are under development.","wpcf-article_keywords":"Advanced glycation end-products, diabetic nephropathy, EMT, podocytes, RAGE, treatment","wpcf-article_citation_override":"European Endocrinology, <\/i>2012;8(2):84-88 DOI: http:\/\/doi.org\/10.17925\/EE.2012.08.02.84<\/a>","wpcf-compliance-with-ethics":"","wpcf-article_disclosure":"The authors have no conflicts of interest to declare.","wpcf-review_process":"","wpcf-authorship":"","wpcf-article_correspondence":"Ma\u00eft\u00e9 Daroux, Department of Nephrology, Duchenne Hospital, BP 609, 62321 Boulogne-sur-Mer Cedex, France. E: m.daroux@ch-boulogne.fr","wpcf-article_support":"","wpcf-open_access":"","wpcf-article_pdf":"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2015\/06\/daroux.pdf","wpcf-article_pdf-gated":true,"wpcf-article_doi":"","wpcf-old_nid":"","wpcf-article_image":"","wpcf-editor_choice":false,"wpcf-old_author_ids":"","wpcf-article_references":"

    \r\n\r\n
  1. Brownlee M, Biochemistry and molecular cell biology of\r\ndiabetic complications, Nature, 2001;13:813\u201320.\r\n
  2. Maillard LC, Action des acides amin\u00e9s sur les sucres:\r\nformation des m\u00e9lano\u00efdines par voie m\u00e9thodique,\r\nCR Acad Sci, 1912;154:66\u20138.\r\n
  3. Boulanger E, Wautier JL, Dequiedt P, Schmidt AM,\r\nGlycation, glycoxidation and diabetes mellitus,\r\nNephrol Ther, 2006;(2 Suppl. 1):S8\u201316.\r\n
  4. Ohgami N, Nagai R, Ikemoto M, et al., CD36, a member of\r\nclass B scavenger receptor family, is a receptor for\r\nadvanced glycation end products, Ann N Y Acad Sci,\r\n2001;947:350\u20135.\r\n
  5. Iacobini C, Amadio L, Oddi G, et al., Role of galectin-3 in\r\ndiabetic nephropathy, J Am Soc Nephrol,\r\n2003;14(8 Suppl. 3):S264\u201370.\r\n
  6. Neeper M, Schmidt AM, Brett J, et al. Cloning and\r\nexpression of a cell surface receptor for advanced\r\nglycosylation end products of proteins, J Biol Chem,\r\n1992;267:14998\u20135004.\r\n
  7. Thornalley PJ, Cell activation by glycated proteins. AGE\r\nreceptors, receptor recognition factors and functional\r\nclassification of AGEs, Cell Mol Biol, 1998;44:1013\u201323.\r\n
  8. Grossin N, Boulanger E, Wautier MP, Wautier JL, The\r\ndifferent isoforms of the receptor for advanced glycation\r\nend products are modulated by pharmacological agents,\r\nClin Hemorheol Microcirc, 2010;45:143\u201353.\r\n
  9. Wendt TM, Tanji N, Guo J, et al. RAGE drives the\r\ndevelopment of glomerulosclerosis and implicates podocyte\r\nactivation in the pathogenesis of diabetic nephropathy,\r\nAm J Pathol, 2003;162:1123\u201337.\r\n
  10. Wautier MP, Chappey O, Corda S, et al., Activation of\r\nNADPH oxidase by AGE links oxidant stress to altered\r\ngene expression via RAGE, Am J Physiol Endocrinol Metab,\r\n2001;280:E685\u201394.\r\n
  11. Vlassara H, Striker LJ, Teichberg S, et al., Advanced\r\nglycation end products induce glomerular sclerosis and\r\nalbuminuria in normal rats, Proc Natl Acad Sci USA,\r\n1994;91(24):11704\u20138.\r\n
  12. Bohlender JM, Franke S, Stein G, Wolf G, Advanced glycation\r\nend products and the kidney, Am J Physiol Renal Physiol,\r\n2005;289:F645\u201359.\r\n
  13. D'Agati V, Yan SF, Ramasamy R, Schmidt AM, RAGE,\r\nglomerulosclerosis and proteinuria: roles in podocytes and\r\nendothelial cells, Trends Endocrinol Metab, 2010;21:50\u20136.\r\n
  14. Li JJ, Kwak SJ, Jung DS, et al., Podocyte biology in diabetic\r\nnephropathy, Kidney Int, 2007;(Suppl.):S36\u201342.\r\n
  15. Chuang PY, Yu Q, Fang W, et al., Advanced glycation\r\nendproducts induce podocyte apoptosis by activation of the\r\nFOXO4 transcription factor, Kidney Int, 2007;72:965\u201376.\r\n
  16. Diez-Sampedro A, Lenz O, Fornoni A, Podocytopathy\r\nin diabetes: a metabolic and endocrine disorder,\r\nAm J Kidney Dis, 2011;58(4):637\u201346.\r\n
  17. Bondeva T, Wojciech S, Wolf G, Advanced glycation end\r\nproducts inhibit adhesion ability of differentiated podocytes\r\nin a neuropilin-1-dependent manner, Am J Physiol Renal Physiol,\r\n2011;301:852\u201370.\r\n
  18. Ha TS, High-glucose and advanced glycosylation end\r\nproducts increased podocyte permeability via PI3-K\/Akt\r\nsignaling, J Mol Med, 2010;88:391\u2013400.\r\n
  19. Ha TS, High glucose and advanced glycosylated\r\nend-products affect the expression of alpha-actini-4 in\r\nglomerular epithelial cells, Nephrology, 2006;11:435\u201341.\r\n
  20. Berrou J, Tostivint I, Verrecchia F, et al., Advanced glycation\r\nend products regulate extracellular matrix protein and\r\nprotease expression by human glomerular mesangial cells,\r\nInt J Mol Med, 2009;23:513\u201320.\r\n
  21. Kim KM, Kim YS, Jung DH, et al., Increased glyoxalase I\r\nlevels inhibit accumulation of oxidative stress and an\r\nadvanced glycation end product in mouse mesangial cells\r\ncultured in high glucose, Exp Cell Res, 2012;318:152\u20139.\r\n
  22. Burns WC, Twigg SM, Forbes JM, et al. Connective tissue\r\ngrowth factor plays an important role in advanced glycation\r\nend product-induced tubular epithelial-to-mesenchymal\r\ntransition: implications for diabetic renal disease,\r\nJ Am Soc Nephrol, 2006;17:2484\u201394.\r\n
  23. Chabroux S, Canoui-Poitrine F, Reffet S, et al., Advanced\r\nglycation end products assessed by skin autofluorescence\r\nin type 1 diabetics are associated with nephropathy, but\r\nnot retinopathy, Diabetes Metab, 2010;36:152\u20137.\r\n
  24. Miyata T, Ueda Y, Shinzato T, et al., Accumulation of\r\nalbumin-linked and free-form pentosidine in the circulation\r\nof uremic patients with end-stage renal failure: renal\r\nimplications in the pathophysiology of pentosidine,\r\nJ Am Soc Nephrol, 1996;7:1198\u2013206.\r\n
  25. Goldberg T, Cai W, Peppa M, et al., Advanced glycoxidation\r\nend products in commonly consumed foods, J Am Diet Assoc,\r\n2004;104:1287\u201391.\r\n
  26. Koschinsky T, He CJ, Mitsuhashi T, et al., Orally absorbed\r\nreactive glycation products (glycotoxins): an environmental\r\nrisk factor in diabetic nephropathy, Proc Natl Acad Sci USA,\r\n1997;94:6474\u20139.\r\n
  27. Sebekova K, Somoza V, Dietary advanced glycation\r\nendproducts (AGEs) and their health effects\u2013pro,\r\nMol Nutr Food Res, 2007;51:1079\u201384.\r\n
  28. Buetler T, The health risks of dietary advanced glycation\r\nend-products. Interview by Monika Pischetsrieder,\r\nMol Nutr Food Res, 2007;51:1071\u20133.\r\n
  29. Henle T, Dietary advanced glycation end products\u2013a risk to\r\nhuman health? A call for an interdisciplinary debate,\r\nMol Nutr Food Res, 2007;51:1075\u20138.\r\n
  30. Ames JM, Evidence against dietary advanced glycation\r\nendproducts being a risk to human health, Mol Nutr Food Res,\r\n2007;51:1085\u201390.\r\n
  31. Negrean M, Stirban A, Stratmann B, et al., Effects of\r\nlow- and high-advanced glycation endproduct meals\r\non macro- and microvascular endothelial function and\r\noxidative stress in patients with type 2 diabetes mellitus,\r\nAm J Clin Nutr, 2007;85(5):1236\u201343.\r\n
  32. Thornalley PJ, Use of aminoguanidine (Pimagedine) to\r\nprevent the formation of advanced glycation endproducts,\r\nArch Biochem Biophys, 2003;419:31\u201340.\r\n
  33. Bolton WK, Cattran DC, Williams ME, et al., Randomized trial\r\nof an inhibitor of formation of advanced glycation\r\nend products in diabetic nephropathy, Am J Nephrol,\r\n2004;24:32\u201340.\r\n
  34. Alkhalaf A, Klooster A, van Oeveren W, et al., A\r\ndouble-blind, randomized, placebo-controlled clinical\r\ntrial on benfotiamine treatment in patients with diabetic\r\nnephropathy, Diabetes Care, 2010;33:1598\u2013601.\r\n35. Williams M, A phase 2 clinical trial of Pyridorin in type\r\n1diabetic patients with overt nephropathy, JASN, 2003;14:7A.\r\n
  35. McGill JB, Degenhardt TP, Szabo JR, et al., A phase 2 clinical\r\ninvestigation of pyridoxamine (Pyridorin) in type 1 and type\r\n2 diabetic patients with overt diabetic nephropathy (PYR-\r\n205\/207), Diabetes, 2004;53:581\u2013P.\r\n
  36. Figarola JL, Scott S, Loera S, et al., LR-90 a new advanced\r\nglycation endproduct inhibitor prevents progression of\r\ndiabetic nephropathy in streptozotocin-diabetic rats,\r\nDiabetologia, 2003;46:1140\u201352.\r\n
  37. Figarola JL SS, Loera S, et al., Prevention of early renal\r\ndisease, dyslipidemia and lipid peroxidation in STZ-diabetic\r\nrats by LR-9 and LR-74 novel AGE inhibitors, Diabetes Metab\r\nRes Rev, 2005;21:533\u201344.\r\n
  38. Forbes JM, Thallas V, Thomas MC, et al., The breakdown of\r\npreexisting advanced glycation end products is associated\r\nwith reduced renal fibrosis in experimental diabetes,\r\nFASEB J, 2003;17:1762\u20134.\r\n
  39. Chandra KP, Shiwalkar A, Kotecha J, et al., Phase I\r\nclinical studies of the advanced glycation end-product\r\n(AGE)-breaker TRC4186: safety, tolerability and\r\npharmacokinetics in healthy subjects, Clin Drug Investig,\r\n2009;29:559\u201375.\r\n
  40. Joshi D, Gupta R, Dubey A, et al., TRC4186, a novel\r\nAGE-breaker, improves diabetic cardiomyopathy and\r\nnephropathy in Ob-ZSF1 model of type 2 diabetes,\r\nJ Cardiovasc Pharmacol, 2009;54:72\u201381.\r\n
  41. Sourris KC, Morley AL, Koitka A, et al., Receptor for AGEs\r\n(RAGE) blockade may exert its renoprotective effects in\r\npatients with diabetic nephropathy via induction of the\r\nangiotensin II type 2 (AT2) receptor, Diabetologia,\r\n2010;53(11):2442\u201351.\r\n
  42. Jensen LJ, Denner L, Schrijvers BF, et al., Renal effects of a\r\nneutralising RAGE-antibody in long-term streptozotocindiabetic\r\nmice, J Endocrinol, 2006;188:493\u2013501.\r\n
  43. Lanati N, Emanuele E, Brondino N, Geroldi D, Soluble\r\nRAGE-modulating drugs: state-of-the-art and future\r\nperspectives for targeting vascular inflammation,\r\nCurr Vasc Pharmacol, 2010;8(1):86\u201392.\r\n
  44. Forbes JM, Thorpe SR, Thallas-Bonke V, et al., Modulation of\r\nsoluble receptor for advanced glycation end products by\r\nangiotensin-converting enzyme-1 inhibition in diabetic\r\nnephropathy, J Am Soc Nephrol, 2005;16:2363\u201372.\r\n
  45. Ishibashi Y, Yamagishi SI, Matsui T, et al., Pravastatin\r\ninhibits advanced glycation end products (AGEs)-induced\r\nproximal tubular cell apoptosis and injury by reducing\r\nreceptor for AGEs (RAGE) level, Metabolism,\r\n2012;61(8):1067\u201372.\r\n
  46. Li YB, Yin JJ, Wang HJ, et al., Effect of simvastatin on\r\nexpression of transforming growth factor-beta and collagen\r\ntype IV in rat mesangial cells, Pharmacology, 2011;88:188\u201392.\r\n
  47. Lu L, Peng WH, Wang W, Effects of atorvastatin on\r\nprogression of diabetic nephropathy and local RAGE\r\nand soluble RAGE expressions in rats, J Zhejiang Univ Sci B,\r\n2011;12:652\u20139.\r\n
  48. Tam HL, Shiu SW, Wong Y, et al., Effects of atorvastatin\r\non serum soluble receptors for advanced glycation endproducts\r\nin type 2 diabetes, Atherosclerosis, 2010;209:173\u20137.\r\n\r\n\r\n<\/ol>","wpcf-article_received_date":"2012-07-05T00:00:00","wpcf-article_accepted_date":"2012-08-17T00:00:00","wpcf-article_published_online":null,"wpcf-podcast":"","wpcf-ogg":"","wpcf-article_end_page":"88","wpcf-article_start_page":"84","wpcf-acknowledgements":"","wpcf-errata_pdf":"","wpcf-article_flipper_image":"","wpcf-corrected_online":null,"wpcf-supplementary_information":"","wpcf-article_highlight_pdf":"","data_availability":"","digital_features":""},"_links":{"self":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/1107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/comments?post=1107"}],"version-history":[{"count":0,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/1107\/revisions"}],"wp:attachment":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media?parent=1107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/categories?post=1107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/tags?post=1107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}